Education
About Us
Working with TipRanks
Follow Us
Bright Minds Biosciences (TSE:DRUG)
:DRUG
RESEARCH TOOLSreports
DRUG Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$1.29 - C$108.00
Previous CloseN/A
Volume70.00
Average Volume (3M)534.00
Market Cap
C$367.48M
Enterprise ValueC$239.48K
Total Cash (Recent Filing)C$57.90M
Total Debt (Recent Filing)C$182.73K
Price to Earnings (P/E)―
Beta26.16
Next Earnings
May 14, 2025EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding7,043,989
10 Day Avg. Volume609
30 Day Avg. Volume534
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$127.27Price Target Upside143.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bright Minds Biosciences News
PremiumCompany Announcements
Bright Minds Biosciences to Engage in Key Healthcare Conferences
PremiumCompany Announcements
Bright Minds Biosciences Shows Financial Improvement in Latest Report
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentBMB-101 is on track for a readout that should de-risk the program, with a Phase 2 trial evaluating it as a potential best-in-class therapy for developmental and epileptic encephalopathies and absence epilepsy.
Financial StabilityBright Minds Biosciences has an adequate cash position to support operations for the next 12 months, indicating financial stability.
Strategic AcquisitionThe recent $2.6B acquisition of Longboard Pharmaceuticals validates the 5-HT2C agonist MoA value proposition with positive data driving strategic interest.
Bears Say
Competitive LandscapeBMB-101 has potential advantages over similar compounds, such as the potential for less frequent dosing and improved selectivity.
Market ExpectationsThe Ph2 BREAKTHROUGH topline data is expected to drive share movement and potentially close the valuation gap with a growing portfolio of 5-HT assets.
---
Options Prices
Currently, No data available
---
Ownership Overview
30.50% Insiders
―
Mutual Funds
54.65% Other Institutional Investors
14.68% Public Companies and
Individual Investors
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was C$1.29 and its highest was C$108.00 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is C$367.48M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is May 14, 2025 which is in 41 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on Feb 13, 2025. The company reported C$0.01 earnings per share for the quarter, beating the consensus estimate of N/A by C$0.01.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -0.46.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 7,043,989 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of C$0.01 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.362%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in TSE:DRUG
---
Bright Minds Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$127.27 (143.91% Upside)
C$127.27 (143.91% Upside)
Blogger Sentiment
Bullish
TSE:DRUG Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth C$258.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3425.67%
12-Months-Change
Fundamentals
Return on Equity
-3.35%
Trailing 12-Months
Asset Growth
747.95%
Trailing 12-Months
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
---
DRUG Stock 12 Month Forecast
Average Price Target
C$127.27
▲(143.91% Upside)
Technical Analysis
Best Analysts Covering DRUG
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-0.35%
reiterated a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -0.35% per trade.
---